Depression (Major Depressive Disorder) A Randomized Clinical Trial of Bupropion and Paroxetine for the Treatment of High-Risk Major Depressive Disorder

Contact name: Lucia Sanchez-Diaz

Phone: (212)-543-6216

Fax: (212)-543-6017

Email: lsanchez@neuron.cpmc.columbia.edu

Disorder: Major Depressive Disorder

Geographic location: Columbia University, New York, NY

Other keywords:

Participant compensation: Free medication management for six months

Time commitment required: Weekly visit for 8 weeks, then monthly visits

Drug trial: Yes

Recruitment end date (approximate): June 2007

Study criteria (i.e., age or gender requirements):
-Between 18 and 75 years old
-Currently in a Major Depressive Episode
-History of a past suicide attempt
-Must live within the New York City metro area, since patients are required to come in regularly for psychopharmacological treatment visits

Exclusion criteria:
-History of Bipolar Disorder or psychotic symptoms
-Responded poorly to paroxetine or bupropion in the past
-Drug or alcohol dependence
-Past or current anorexia or bulimia nervosa
-Unstable medical illness

Brief description of study:
The Department of Neuroscience at Columbia University and the New York State Psychiatric Institute is conducting a research study on the prevention of suicidal behavior in Major Depressive Disorder using medications, and is looking for people interested in participating. The goal of our study is to compare the effect of bupropion versus paroxetine on the vulnerability to suicidal behavior during a 6-month period following a Major Depressive Episode. Both bupropion and paroxetine are antidepressants which have been approved by the Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder.
We are offering free outpatient medication monitoring visits at the Neuroscience Clinic for a period of 6 months in return for participation in the study.

Additional information: